Anti-Gliadin IgA / sIgA

Celiac disease is a chronic illness of the small intestinal mucous membrane. The reason is an intolerance against gluten, which is found in many cereals.

The intake of gluten-containing food leads to an inflammation of the small intestinal mucous membrane. The resorption of nutrients is reduced. The symptoms of the disease are reduction of weight, diarrhoea, vomitus, anorexia and tiredness. The growth of children is reduced. The characteristic of the symptoms might be different. The only therapeutic treatment is a gluten-free diet. A non-treated celiac disease increases the risk of non-Hodgkin-lymphoma and colon cancer. In five to ten percent of the patients celiac disease is associated with diabetes mellitus type 1. Women are more often affected than men. The outcome of the disease is pronounced during infancy and in an age between 30 and 40 years.


  • Food intolerance
  • Monitoring of a elimination diet

Technical data

Sample Stool
Sample volume 100 mg, 100 µl
Calibration 5 point
Incubation time 1h, 1h, 15 min
Method ELISA
Determinations 96

Ordering Information

IC6300 Testkit

Principle of the method

The anti-gliadin-ELISA test determines human anti-gliadin sIgA / IgA antibodies according to the “sandwich”-principle. Anti-gliadin antibodies in sample, standard and controls bind to gliadin, which is coated to the microtiterplate. After a washing step a peroxidase labeled detection antibody is added. A second washing step is followed by the addition of the substrate which is converted to a colored product by the peroxidase. The reaction is terminated by the addition of an acidic stop solution. The optical densities are read at 450 nm in a microtiterplate reader. The anti-gliadin concentration can be calculated from the standard curve.